|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistitics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ding J and Wang H: Multiple interactive
factors in hepatocarcinogenesis. Cancer Lett. 346:17–23. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
4
|
Miamen AG, Dong H and Roberts LR:
Immunotherapeutic approches to hepatocellular carcinoma treatment.
Liver Cancer. 1:226–237. 2012. View Article : Google Scholar
|
|
5
|
Yuen MF, Hou JL and Chutaputti A; Asia
Pacific Working Party on Prevention of Hepatocellular Carcinoma.
Hepatocellular carcinoma in the Asia pacific region. J
Gastroenterol Hepatol. 24:346–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Trepo C: A brief history of hepatitis
milestones. Liver Int. 34(Suppl 1): 29–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishikawa T: Anti-viral therapy to reduce
recurrence and improve survival in hepatitis B virus-related
hepatocellular carcinoma. World J Gastroenterol. 19:8861–8866.
2013. View Article : Google Scholar :
|
|
8
|
Malek NP, Schmidt S, Huber P, Manns MP and
Greten TF: The diagnosis and treatment of hepatocellular carcinoma.
Dtsch Arztebi Int. 111:101–106. 2014.
|
|
9
|
Lopez LJ and Marrero JA: Hepatocellular
carcinoma. Curr Opin Gastroenterol. 20:248–253. 2004. View Article : Google Scholar
|
|
10
|
Shen Y, Lin ZZ, Hsu CH, Hsu C, Hsu C, Shao
YY and Cheng AL: Clinical trials in hepatocellular carcinoma: an
update. Liver Cance. 2:345–364. 2013. View Article : Google Scholar
|
|
11
|
Sasaki K, Matsuda M, Ohkura Y, Kawamura Y,
Inoue M, Hashimoto M, Ikeda K, Kumada H and Watanabe G: In
hepatocellular carcinomas, any proportion of poorly differentiated
components is associated with poor prognosis after hepatectomy.
World J Surg. 38:1147–1153. 2014. View Article : Google Scholar
|
|
12
|
Lin S, Hoffmann K and Schemmer P:
Treatment of hepatocellular carcinoma: a systematic review. Liver
Cancer. 1:144–158. 2012. View Article : Google Scholar
|
|
13
|
Singal AK, Guturu P, Hmoud B, Kuo YF,
Salameh H and Wiesner RH: Evolving frequency and outcomes of liver
transplantation based on etiology of liver disease. Transplanation.
95:755–760. 2013. View Article : Google Scholar
|
|
14
|
Jiang L, Yan L, Wen T, et al: Hepatitis B
prophylaxis using lamivudine and individualized low-dose hepatitis
B immunoglobulin in living donor liver transplantation. Transplant
Proc. 45:2326–2330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vitale A, Volk M and Cillo U: Transplant
benefit for patients with hepatocellular carcinoma. World J
Gastroenterol. 19:9183–9188. 2013. View Article : Google Scholar
|
|
16
|
Fang Y, Chen W, Liang X, Li D, Lou H, Chen
R, Wang K and Pan H: Comparison of long-term effectiveness and
complications of radiofrequency ablation with hepatectomy for small
hepatocellular carcinoma. J Gastroenterol Hepatol. 29:193–200.
2014. View Article : Google Scholar
|
|
17
|
Wang Y, Luo Q, Li Y, Deng S, Wei S and Li
X: Radiofrequency ablation versus hepatic resection for small
hepatocellular carcinomas: a meta-analysis of randomized and
nonrandomized controlled trials. PloS One. 9:e844842014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cucchetti A, Piscaqlia F, Cescon M,
Ercolani G and Pinna AD: Systematic review of surgical resection vs
radiofrequency ablation for hepatocellular carcinoma. World J
Gastroenterol. 19:4106–4188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang T, Zhang J, Lu JH, Yang LQ, Yang GS,
Wu MC and Yu WF: A new staging system for resectable hepatocellular
carcinoma: comparison with six existing staging systems in a large
Chinese cohort. J Cancer Res Clin Oncol. 137:739–750. 2011.
View Article : Google Scholar
|
|
20
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
DuBray BJ Jr, Chapman WC and Anderson CD:
Hepatocellular carcinoma: a review of the surgical approaches to
management. Mo Med. 108:195–198. 2011.PubMed/NCBI
|
|
22
|
Salhab M and Canelo R: An overview of
evidence-based management of hepatocellular carcinoma: a
meta-analysis. J Cancer Res Ther. 7:463–475. 2011. View Article : Google Scholar
|
|
23
|
Young AL, Adair R, Prasad KR, Toogood GJ
and Lodge JP: Hepatocellular carcinoma within a noncirrhotic,
nonfibrotic, seronegative liver: surgical approaches and outcomes.
J Am Coll Surg. 214:174–183. 2012. View Article : Google Scholar
|
|
24
|
Gluer AM, Cocco N, Laurence JM, Johnston
ES, Hollands MJ, Pleass HC, Richardson AJ and Lam VW: Systematic
review of actual 10-year survival following resection for
hepatocellular carcinoma. HPB (Oxford). 14:285–290. 2012.
View Article : Google Scholar
|
|
25
|
Rahbari NN, Wente MN, Schemmer P, Diener
MK, Hoffmann K, Motschall E, Schmidt J, Weitz J and Büchler MW:
Systematic review and meta-analysis of the effect of portal triad
clamping on outcome after hepatic resection. Br J Surg. 95:424–432.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liao X, Chen L, Fu W and Zhou J:
Heparin-binding epidermal growth factor-like growth factor protects
rat intestine after portal triad clamping. Growth Factors.
31:74–80. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang PF, Li CH, Chen YW, Zhang AQ, Cai SW
and Dong JH: Preserving hepatic artery flow during portal triad
blood inflow occlusion improves remnant liver regeneration in rats
after partial hepatectomy. J Surg Res. 181:329–336. 2013.
View Article : Google Scholar
|
|
28
|
Rammohan A, Sathyanesan J, Ramaswami S,
Lakshmanan A, Senthil-Kumar P, Srinivasan UP, Ramasamy R and
Ravichandran P: Embolization of liver tumors: Past, present and
future. World J Radiol. 4:405–412. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi JY: Treatment algorithm for
intermediate and advanced stage hepatocellular carcinoma: Korea.
Oncology. 81(Suppl 1): 141–147. 2011. View Article : Google Scholar
|
|
30
|
Fan ST, Mau Lo C, Poon RT, et al:
Continuous improvement of survival outcomes of resection of
hepatocellular carcinoma: a 20-year experience. Ann Surg.
253:745–758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xi T, Lai EC, Min AR, Shi LH, Wu D, Xue F,
Wang K, Yan Z, Xia Y, Shen F, et al: Adjuvant transatheter arterial
chemoembolization after curative resection of hepatocellular
carcinoma: a non-randomized comparative study.
Hepatogastroenterology. 59:1198–1203. 2012.PubMed/NCBI
|
|
32
|
Shirable K, Wakiyama S, Gion T, Motomura
K, Koyanagi T, Sakamoto S and Nagaie T: Clinicopathological risk
factors linked to recurrence pattern after curative hepatic
resection for hepatocellular carcinoma - results of 152 resected
cases. Hepatogastroenterology. 54:2084–2087. 2007.
|
|
33
|
Ho CM, Wu CY, Lee PH, Lai HS, Ho MC, Wu YM
and Hu RH: Analysis of the risk factors of untransplantable
recurrence after primary curative resection for patients with
hepatocellular carcinoma. Ann Surg Oncol. 20:2526–2533. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Severi T, van Malenstein H, Verslype C and
van Pelt JF: Tumor initiation and progression in hepatocellular
carcinoma: risk factors, classification, and therapeutic targets.
Acta Pharmacol Sin. 31:1409–1420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang H and Chen L: Tumor microenvironment
and hepatocellular carcinoma metastasis. J Gastroenterol Hepatol.
28(Suppl 1): 43–48. 2013. View Article : Google Scholar
|
|
36
|
Xu J, Xu HY, Zhang Q, Song F, Jiang JL,
Yang XM, Mi L, Wen N, Tian R, Wang L, et al: HAb18G/CD147 functions
in invasion and metastasis of hepatocellular carcinoma. Mol Cancer
Res. 5:605–614. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhong B, Huang MP, Yin GQ and Gao X:
Effects of costimulation on intrahepatic immunopathogenesis in
patients with chronic HBV infection. Inflamm Res. 63:217–229. 2014.
View Article : Google Scholar :
|
|
38
|
Wong GL, Chan HL, Tse YK, Lo AO and Wong
VW: On-treatment alpha-fetoprotein is a specific tumor marker for
hepatocellular carcinoma in patients with chronic hepatitis B
receiving entecavir. Hepatology. 59:986–995. 2014. View Article : Google Scholar
|
|
39
|
Abu-Amara M and Feld JJ: Does antiviral
therapy for chronic hepatitis B reduce the risk of hepatocellular
carcinoma? Semin Liver Dis. 33:157–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brechot C, Kremsdorf D, Soussan P, Pineau
P, Dejean A, Paterlini-Brechot P and Tiollais P: Hepatitis B virus
(HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms
and novel paradigms. Pathol Biol (Paris). 58:278–287. 2010.
View Article : Google Scholar
|
|
41
|
Kew MC: Hepatocellular carcinoma in
African blacks: Recent progress in etiology and pathogenesis. World
J Hepatol. 2:65–73. 2010.PubMed/NCBI
|
|
42
|
Chen L, Zhang Q, Chang W, Du Y, Zhang H
and Cao G: Viral and host inflammation-related factors that can
predict the prognosis of hepatocellular carcinoma. Eur J Cancer.
48:1977–1987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chan HL and Sung JJ: Hepatocellular
carcinoma and hepatitis B virus. Semin Liver Dis. 26:153–161. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL,
Tsai KS and Chen CJ: Long-term tracking of hepatitis B viral load
and the relationship with risk for hepatocellular carcinoma in men.
Carcinogenesis. 29:106–112. 2008. View Article : Google Scholar
|
|
45
|
Sun Y, Chen TY, Lu PX, Wang JB, Wu Y,
Zhang QN, Qian GS and Tu H: Relationship between serum hepatitis B
virus DNA load and hepatocellular carcinoma in Qidong, China: a
cohort follow-up study of 14 years. Zhonghua Yi Xue Za Zhi.
92:1874–1877. 2012.(In Chinese). PubMed/NCBI
|
|
46
|
Pan W, Cheng G, Xing H, Shi J, Lu C, Wei
J, Li L, Zhou C, Yuan Q, Zhou L and Yang M: Leukocyte telomere
length-related rs621559 and rs398652 genetic variants influence
risk of HBV-related hepatocellular carcinoma. PLoS One.
9:e1108632014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ke Y, Wang L, Li LQ and Zhong JH:
Nucleos(t)ide analogues to treat hepatitis B virus-related
hepatocellular carcinoma after radical resection. World J Hepatol.
6:653–659. 2014. View Article : Google Scholar
|
|
48
|
Sohn W, Paik YH, Kim JM, Kwon CH, Joh JW,
Gwak GY, Choi MG, Lee JH, Koh KC, Paik SW and Yoo BC: HBV DNA and
HBsAg levels as risk predictors of early and late recurrence after
curative resection of HBV-related hepatocellular carcinoma. Ann
Surg Oncol. 21:2429–2435. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xia F, Lai EC, Lau WY, Ma K, Li X, Bie P
and Qian C: High serum hyaluronic acid and HBV viral load are main
prognostic factors of local recurrence after complete
radiofrequency ablation of hepatitis B-related small hepatocellular
carcinoma. Ann Surg Oncol. 19:1284–1291. 2012. View Article : Google Scholar
|
|
50
|
An HJ, Jang JW, Bae SH, Choi JY, Cho SH,
Yoon SK, Han JY, Lee KH, Kim DG and Jung ES: Sustained low
hepatitis B viral load predicts good outcome after curative
resection in patients with hepatocellular carcinoma. J
Gastroenterol Hepatol. 25:1876–1882. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Deng Y, Du Y, Zhang Q, Han X and Cao G:
Human cytidine deaminases facilitate hepatitis B virus evolution
and link inflammation and hepatocellular carcinoma. Cancer Lett.
343:161–171. 2014. View Article : Google Scholar
|
|
52
|
McMahon BJ: Chronic hepatitis B virus
infection. Med Clin North Am. 98:39–54. 2014. View Article : Google Scholar
|
|
53
|
Su CH, Lin Y and Cai L: Genetic factors,
viral infection, other factors and liver cancer: an update on
current progress. Asian Pac J Cancer Prev. 14:4953–4960. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Shi L, Feng Y, Lin H, Ma R and Cai X: Role
of estrogen in hepatocellular carcinoma: is inflammation the key? J
Transl Med. 12:932014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Höner Zu, Siederdissen C and Cornberg M:
The role of HBsAg levels in the current management of chronic HBV
infection. Ann Gastroenterol. 27:105–112. 2014.
|
|
56
|
Khaliq S, Latief N and Jahan S: Role of
different regions of the hepatitis C virus genome in the
therapeutic response to interferon-based treatment. Arch Virol.
159:1–15. 2014. View Article : Google Scholar
|
|
57
|
Qashqari H, Al-Mars A, Chaudhary A,
Abuzenadah A, Damanhouri G, Alqahtani M, Mahmoud M, El Sayed Zaki
M, Fatima K and Qadr I: Understanding the molecular mechanism(s) of
hepatitis C virus (HCV) induced interferon resistance. Infect Genet
Evol. 19:113–119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Herzer K, Hofmann TG, Teufel A, Schimaski
CC, Moehler M, Kanzler S, Schulze-Bergkamen H and Galle PR:
IFN-α-induced apoptosis in hepatocellular carcinoma involves
promyelocytic leukemia protein and TRAIL independently of p53.
Cancer Res. 69:855–862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lamm D, Brausi M, O’Donnell MA and Witjes
A: Interferon alfa in the treatment paradigm for
non-muscle-invasive bladder cancer. Urol Oncol. 32:35.e21–35.e30.
2014. View Article : Google Scholar
|
|
60
|
Yang YF, Zhao W, Zhong YD, Yang YJ, Shen
L, Zhang N and Huang P: Comparison of the efficacy of thymosin
alpha-1 and interferon alpha in the treatment of chronic hepatitis
B: a meta-analysis. Antiviral Res. 77:136–141. 2008. View Article : Google Scholar
|
|
61
|
Schweizer M, Mätzener P, Pfaffen G,
Stalder H and Peterhans E: ‘Self’ and ‘nonself’ manipulation of
interferon defense during persistent infection: bovine viral
diarrhea virus resists alpha/beta interferon without blocking
antiviral activity against unrelated viruses replicating in its
host cells. J Virol. 80:6926–6935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wilden H, Schirrmacher V and Fournier P:
Important role of interferon regulatory factor (IRF)-3 in the
interferon response of mouse macrophages upon infection by
Newcastle disease virus. Int J Oncol. 39:493–504. 2011.PubMed/NCBI
|
|
63
|
Liu Y, Lou G, Wu W, Shi Y, Zheng M and
Chen Z: Interferon-α sensitizes HBx-expressing hepatocarcinoma
cells to chemotherapeutic drugs through inhibition of HBx-mediated
NF-κB activation. Virol J. 10:1682013. View Article : Google Scholar
|
|
64
|
Cabrera R, Ararat M, Cao M, Xu Y,
Wasserfall C, Atkinson MA, Liu C and Nelson DR: Hepatocellular
carcinoma immunopathogenesis: clinical evidence for global T cell
defects and an immunomodulatory role for soluble CD25 (sCD25). Dig
Dis Sci. 55:484–495. 2010. View Article : Google Scholar
|
|
65
|
Hou ZH, Han QJ, Zhang C, Tian ZG and Zhang
J: miR146a impairs the IFN-induced anti-HBV immune response by
downregulating STAT1 in hepatocytes. Liver Int. 34:58–68. 2014.
View Article : Google Scholar
|
|
66
|
Alcantara FF, Tang H and McLachlan A:
Functional characterization of the interferon regulatory element in
the enhancer 1 region of the hepatitis B virus genome. Nucleic
Acids Res. 30:2068–2075. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Belloni L, Allweiss L, Guerrieri F,
Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M
and Levrero M: IFN-α inhibits HBV transcription and replication in
cell culture and in humanized mice by targeting the epigenetic
regulation of the nuclear cccDNA minichromosome. J Clin Invest.
122:529–537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yang D, Zuo C, Wang X, Meng X, Xue B, Liu
N, Yu R, Qin Y, Gao Y, Wang Q, et al: Complete replication of
hepatitis B virus and hepatitis C virus in a newly developed
hepatoma cell line. Proc Natl Acade Sci USA. 111:E1264–E1273. 2014.
View Article : Google Scholar
|
|
69
|
Sung JJ, Tsoi KK, Wong VW, Li KC and Chan
HL: Meta-analysis: Treatment of hepatitis B infection reduces risk
of hepatocellular carcinoma. Aliment Pharmacol Ther. 28:1067–1077.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xiaobin F, Shuguo Z, Jian Z, Yudong Q,
Lijian L, Kuansheng M, Xiaowu L, Feng X, Dong Y, Shuguang W, et al:
Effect of the pringle maneuver on tumor recurrence of
hepatocellular carcinoma after curative resection (EPTRH): a
randomized, prospective, controlled multicenter trial. BMC Cancer.
12:3402012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Torzilli G, Donadon M and Cimino M: Are
tumor exposure and anatomical resection antithetical during surgery
for hepatocellular carcinoma? A critical review. Liver Cancer.
1:177–182. 2012. View Article : Google Scholar
|
|
72
|
Chen JA, Shi M, Li JQ and Qian CN:
Angiogenesis: multiple masks in hepatocellular carcinoma and liver
regeneration. Hepatol Int. 4:537–547. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhung L, Zeng X, Yang Z and Meng Z: Effect
and safety of interferon for hepatocellular carcinoma: a systematic
review and meta-analysis. PloS One. 8:e613612013. View Article : Google Scholar
|
|
74
|
Qu LS, Jin F, Huang XW and Shen XZ:
Interferon-α therapy after curative resection prevents early
recurrence and improves survival in patients with hepatitic B
virus-related hepatocellular carcinoma. J Surg Oncol. 102:796–801.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Qu LS, Jin F, Huang XW and Shen XZ: High
hepatitis B viral load predicts recurrence of small hepatocellular
carcinoma after curative resection. J Gastrointest Surg.
14:1111–1120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye
QH, Zhang BH, Qian YB, Wu ZQ, Fan J, et al: Postoperative
interferon α treatment postponed recurrence and improved overall
survival in patients after curative resection of HBV-related
hepatocellular carcinoma: a randomized clinical trial. J Cancer Res
Clin Oncol. 132:458–465. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wang J, He XD, Yao N, Liang WJ and Zhang
YC: A meta-analysis of adjuvant therapy after potentially curative
treatment for hepatocellular carcinoma. Can J Gastroenterol.
27:351–363. 2013.PubMed/NCBI
|
|
78
|
Tan ZM and Sun BC: Effects of antiviral
therapy on preventing liver tumorigenesis and hepatocellular
carcinoma recurrence. World J Gastroenterol. 19:8895–8901. 2013.
View Article : Google Scholar :
|
|
79
|
Sun P, Yang X, He RQ, Hu QG, Song ZF,
Xiong J and Zheng QC: Antiviral therapy after curative treatment of
hepatitis B/C virus-related hepatocellular carcinoma: A systematic
review of randomized trials. Hepatol Res. 44:259–269. 2014.
View Article : Google Scholar
|
|
80
|
Chen LT, Chen MF, Li LA, Lee PH, Jeng LB,
Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, et al; Disease Committee of
Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan
Cooperative Oncology Group, National Health Research Institutes,
Zhunan, Taiwan. Long-term results of a randomized, observation
controlled, phase III trial of adjuvant interferon Alfa-2b in
hepatocellular carcinoma after curative resection. Ann Surg.
255:8–17. 2012. View Article : Google Scholar
|
|
81
|
Takaoka A, Hayakawa S, Yanai H, Stoiber D,
Negishi H, Kikuchi H, Sasaki S, Imaki S, Imai K, Shibue T, et al:
Integration of interferon-α/β signalling to p53 responses in tumour
suppression and antiviral defence. Nature. 424:516–523. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Slack FJ and Weidhaas JB: MicroRNA in
cancer prognosis. N Eng J Med. 359:2720–2722. 2008. View Article : Google Scholar
|
|
83
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ji J, Shi J, Budhu A, Yu Z, Forgues M,
Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, et al: MicroRNA
expression, survival, and response to interferon in liver cancer. N
Eng J Med. 361:1437–1447. 2009. View Article : Google Scholar
|
|
86
|
Ji J, Yu Z, Yu Z, Forgues M, Uenishi T,
Kubo S, Wakasa K, Zhou J, Fan J, Tang ZY, et al: Development of a
miR-26 companion diagnostic test for adjuvant interferon-alpha
therapy in hepatocellular carcinoma. Int J Biol Sci. 9:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng
IO, Sun H, Qin L, Qiu S, Lee JM, et al: Hepatic RIG-I predicts
survival and interferon-α therapeutic response in hepatocellular
carcinoma. Cancer Cell. 25:49–63. 2014. View Article : Google Scholar
|
|
88
|
Zhao Y, Cai G, Zhou L, Liu L, Qi X, Bai M,
Li Y, Fan D and Han G: Transarterial chemoembolization in
hepatocellular carcinoma with vascular invasion or extrahepatic
metastasis: A systematic review. Asia Pac J Clin. 9:357–364. 2013.
View Article : Google Scholar
|
|
89
|
Lencioni R: Chemoembolization for
hepatocellular carcinoma. Semin Oncol. 39:503–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chen S, Chen J, Xi W, Xu W and Yin G:
Clinical therapeutic effect and biological monitoring of p53 gene
in advanced hepatocellular carcinoma. Am J Clin Oncol. 37:24–29.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhong JH and Li LQ: Postoperative adjuvant
transarterial chemoembolization for participants with
hepatocellular carcinoma: A meta-analysis. Hepatol Res. 40:943–953.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Matsuda M, Omata F, Fuwa S, Saida Y,
Suzuki S, Uemura M, Ishii N, Iizuka Y, Fukuda K and Fujita Y:
Prognosis of patients with hepatocellular carcinoma treated solely
with transcatheter arterial chemoembolization: risk factors for
one-year recurrence and two-year mortality (preliminary data).
Intern Med. 52:847–853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Breunig IM, Shaya FT, Hanna N, Seal B,
Chirikov VV and Daniel Mullins C: Transarterial chemoembolization
treatment: association between multiple treatments, cumulative
expenditures, and survival. Value Health. 16:760–768. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Nagano H, Sakon M, Eguchi H, Kondo M,
Yamamoto T, Ota H, Nakamura M, Wada H, Damdinsuren B, Marubashi S,
et al: Hepatic resection followed by IFN-α and 5-FU for advanced
hepatocellular carcinoma with tumor thrombus in the major portal
branch. Hepatogastroenterology. 54:172–179. 2007.PubMed/NCBI
|
|
95
|
Choi JW, Park JY, Ahn SH, Yoon KT, Ko HK,
Lee do Y, Lee JT, Kim KS, Choi JS, Han KH, et al: Efficacy and
safety of transarterial chemoembolization in recurrent
hepatocellular carcinoma after curative surgical resection. Am J
Surg Oncol. 32:564–569. 2009. View Article : Google Scholar
|
|
96
|
Li KW, Li X, Wen TF and Lu WS: The effect
of postoperative TACE on prognosis of HCC: an update.
Hepatogastroenterology. 60:248–251. 2013.PubMed/NCBI
|
|
97
|
Tanaka K, Yabushita Y, Nakagawa K,
Kumamoto T, Matsuo K, Taguri M and Endo I: Debulking surgery
followed by intraarterial 5-fluorouracil chemotherapy plus
subcutaneous interferon alfa for massive hepatocellular carcinoma
with multiple intrahepatic metastases: a pilot study. Eur J Surg
Oncol. 39:1364–1370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kumamoto T, Tanaka K, Matsuo K, Takeda K,
Nojiri K, Mori K, Taniguchi K, Matsuyama R, Ueda M, Akiyama H, et
al: Adjuvant hepatic arterial infusion chemotherapy with
5-Fluorouracil and interferon after curative resection of
hepatocellular carcinoma: a preliminary report. Anticancer Res.
33:5585–5590. 2013.PubMed/NCBI
|
|
99
|
Yan Q, Ni J, Zhang GL, Yao X, Yuan WB,
Zhou L and Zheng SS: Efficacy of postoperative antiviral combined
transcatheter arterial chemoembolization therapy in prevention of
hepatitis B-related hepatocellular carcinoma recurrence. Chin Med J
(Engl). 126:855–859. 2013.
|
|
100
|
Xie B, Wang DH and Spechcer SJ: Sorafenib
for treatment of hepatocellular carcinoma: a systematic review. Dig
Dis Sci. 57:1122–1129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zhu AX: Development of sorafenib and other
molecularly targeted agents in hepatocellular carcinoma. Cancer.
112:250–259. 2008. View Article : Google Scholar
|
|
102
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilkie S, Wilhelm S and Lynch M: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al; SHARP Investigators Study Group. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
105
|
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR,
Bhagat N and Geschwind JF: Phase II trial of sorafenib combined
with concurrent transarterial chemoembolization with drug-eluting
beads for hepatocellular carcinoma. J Clin Oncol. 29:3960–3967.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wang SN, Chuang SC and Lee KT: Efficacy of
sorafenib as adjuvant therapy to prevent early recurrence of
hepatocellular carcinoma after curative surgery: A pilot study.
Heptatol Res. 44:523–531. 2014. View Article : Google Scholar
|
|
107
|
Kim R, Menon N and Aucejo F: Safe use of
sorafenib in a patient undergoing salvage liver transplantation for
recurrent hepatocellular carcinoma after hepatic resection. Med
Oncol. 28:1044–1047. 2011. View Article : Google Scholar
|
|
108
|
Kudo M: Adjuvant therapy after curative
treatment for hepatocellular carcinoma. Oncology. 81(Suppl 1):
50–55. 2011. View Article : Google Scholar
|
|
109
|
Kusano H, Ogasawara S, Akiba J, Nakayama
M, Ueda K and Yano H: Antiproliferative effects of sorafenib and
pegylated IFN-α2b on human liver cancer cells in vitro and in vivo.
Int J Oncol. 42:1897–1903. 2013.PubMed/NCBI
|
|
110
|
Wang L, Jia D, Duan F, Sun Z, Liu X, Zhou
L, Sun L, Ren S, Ruan Y and Gu J: Combined anti-tumor effects of
IFN-α and sorafenib on hepatocellular carcinoma in vitro and in
vivo. Biochem Biophy Res Commun. 422:687–692. 2012. View Article : Google Scholar
|
|
111
|
Huang G, Lai EC, Lau WY, Zhou WP, Shen F,
Pan ZY, Fu SY and Wu MC: Posthepatectomy HBV reactivation in
hepatitis B-related hepatocellular carcinoma influences
postoperative survival in patients with preoperative low HBV-DNA
levels. Ann Surg. 257:490–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Su CW, Chiou YW, Tsai YH, Teng RD, Chau
GY, Lei HJ, Hung HH, Huo TI and Wu JC: The influence of hepatitis B
viral load and pre-s deletion mutations on post-operative
recurrence of hepatocellular carcinoma and the tertiary preventive
effects by anti-viral therapy. PloS One. 8:e664572013. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Albert A, Brunetto MR, Colombo M and Craxì
A: Recent progress and new trends in the treatment of hepatitis B.
J Med Virol. 67:458–462. 2002. View Article : Google Scholar
|
|
114
|
Takkenberg RB, Weegink CJ, Zaaijer HL and
Reesink HW: New developments in antiviral therapy for chronic
hepatitis B. Vox Sang. 98:481–494. 2010. View Article : Google Scholar
|
